Enterprise Value

161.6M

Cash

26.0M

Avg Qtr Burn

-4.579M

Short % of Float

14.87%

Insider Ownership

32.20%

Institutional Own.

14.17%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XPro1595 (XPro™) Details
Alzheimer's disease

Phase 2

Data readout

INB03 + trastuzumab-deruxtecan Details
Cancer, Pancreatic cancer, Gastric cancer, HER2-expressing cancers, Breast cancer, Triple-negative breast cancer

Phase 2

Update

XPro1595 (XPro™) (pegipanermin fr) Details
Mental health, Major depressive disorder, Treatment Resistant Depression

Phase 2

Initiation

INKmune™ Details
Cancer, Castration-resistant prostate cancer, Prostate cancer

Phase 1/2

Data readout

INKmune™ Details
Cancer, Acute myeloid leukemia, Myelodysplastic syndrome

Phase 1

Data readout

LIVNate Details
Liver disease, NASH-induced significant or severe fibrosis

Failed

Discontinued

Failed

Discontinued